Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Segment Reporting Information [Line Items]
Total research and development	$ 9,334	$ 4,074
Total general and administrative	5,521	3,797
Loss from operations	(14,855)	(7,871)
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	1,535	1,154
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	0	(127)
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	444	321
QTORIN CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	1,828	785
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	3,190	1,322
Total general and administrative	3,282	1,453
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	1,353	247
Total general and administrative	716	1,062
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	984	1,282
Total general and administrative	$ 1,523	$ 372